RNAC
Cartesian Therapeutics, Inc.
Biotechnology
Market Cap$216M
5Y Perf.-92.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RNAC vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
RNAC vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RNAC | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $216M | $1712.35T |
| Revenue (TTM) | $2M | $0.00 |
| Net Income (TTM) | $-152M | $-168M |
| Gross Margin | -6.3% | — |
| Operating Margin | -51.4% | — |
| Total Debt | $13M | $22M |
| Cash & Equiv. | $125M | $194M |
RNAC vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNAC
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cartesian Therapeut… (RNAC) | 100 | 7.4 | -92.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNAC vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DBVT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Cartesian Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RNAC
Cartesian Therapeutics, Inc.
The Growth Play
RNAC is the clearest fit if your priority is growth exposure.
- Rev growth -92.8%, EPS growth -52.6%, 3Y rev CAGR -70.7%
- -92.8% revenue growth vs DBVT's -100.0%
- -45.1% ROA vs DBVT's -89.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick
DBVT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.26
- -87.0% 10Y total return vs RNAC's -98.1%
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RNAC | -92.8% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs RNAC's -85.5% |
| Stability / Safety | DBVT | Beta 1.26 vs RNAC's 2.03 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs RNAC's -19.6% |
| Efficiency (ROA) | RNAC | -45.1% ROA vs DBVT's -89.0% |
RNAC vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
RNAC vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGRNAC
RNACCartesian Therapeutic…
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs RNACMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
RNAC1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNAC3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RNAC and DBVT operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | RNACCartesian Therape… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $2M | $0 |
| EBITDAEarnings before interest/tax | -$90M | -$112M |
| Net IncomeAfter-tax profit | -$152M | -$168M |
| Free Cash FlowCash after capex | -$77M | -$151M |
| Gross MarginGross profit ÷ Revenue | -6.3% | — |
| Operating MarginEBIT ÷ Revenue | -51.4% | — |
| Net MarginNet income ÷ Revenue | -85.5% | — |
| FCF MarginFCF ÷ Revenue | -43.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -92.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -114.7% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RNAC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | RNACCartesian Therape… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $216M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $104M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -1.63x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 77.34x | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
RNAC leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
RNAC leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs RNAC's 1/9, reflecting mixed financial health.
| Metric | RNACCartesian Therape… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | -45.1% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -25.0% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | -$112M | -$172M |
| Cash & Equiv.Liquid assets | $125M | $194M |
| Total DebtShort + long-term debt | $13M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
RNAC leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $875 for RNAC. Over the past 12 months, DBVT leads with a +110.4% total return vs RNAC's -19.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs RNAC's -38.9% — a key indicator of consistent wealth creation.
| Metric | RNACCartesian Therape… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +20.7% | +4.9% |
| 1-Year ReturnPast 12 months | -19.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | -77.1% | +19.7% |
| 5-Year ReturnCumulative with dividends | -91.3% | -69.1% |
| 10-Year ReturnCumulative with dividends | -98.1% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -38.9% | +6.2% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than RNAC's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs RNAC's 52.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNACCartesian Therape… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.03x | 1.26x |
| 52-Week HighHighest price in past year | $15.57 | $26.18 |
| 52-Week LowLowest price in past year | $5.60 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +52.4% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 68.7 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 225K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RNAC as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 96.1% for RNAC (target: $16).
| Metric | RNACCartesian Therape… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $46.33 |
| # AnalystsCovering analysts | 10 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Total Returns). RNAC leads in 2 (Valuation Metrics, Profitability & Efficiency).
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
RNAC vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RNAC or DBVT a better buy right now?
Analysts rate Cartesian Therapeutics, Inc.
(RNAC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RNAC or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -91. 3% for Cartesian Therapeutics, Inc. (RNAC). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus RNAC's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RNAC or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Cartesian Therapeutics, Inc. 's 2. 03β — meaning RNAC is approximately 61% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — RNAC or DBVT?
On earnings-per-share growth, the picture is similar: Cartesian Therapeutics, Inc.
grew EPS -52. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RNAC or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -46. 6% for Cartesian Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -31. 0% for RNAC. At the gross margin level — before operating expenses — RNAC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RNAC or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RNAC or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, RNAC: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RNAC and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.